JPS6140234B2 - - Google Patents
Info
- Publication number
- JPS6140234B2 JPS6140234B2 JP54093635A JP9363579A JPS6140234B2 JP S6140234 B2 JPS6140234 B2 JP S6140234B2 JP 54093635 A JP54093635 A JP 54093635A JP 9363579 A JP9363579 A JP 9363579A JP S6140234 B2 JPS6140234 B2 JP S6140234B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- group
- group represented
- represented
- integer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960000278 theophylline Drugs 0.000 claims description 46
- 150000001875 compounds Chemical class 0.000 claims description 27
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical class O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 125000005843 halogen group Chemical group 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 238000000921 elemental analysis Methods 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 2
- 229960000876 cinnarizine Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 229960003910 promethazine Drugs 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- RNNVQNMOFQXXTH-UHFFFAOYSA-N 1,4-diazepane-1-carbaldehyde Chemical compound O=CN1CCCNCC1 RNNVQNMOFQXXTH-UHFFFAOYSA-N 0.000 description 1
- MNVGPMNPNODFAY-UHFFFAOYSA-N 1-[(3,4-dichlorophenyl)methyl]-1,4-diazepane Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CCNCCC1 MNVGPMNPNODFAY-UHFFFAOYSA-N 0.000 description 1
- WEUCDJCFJHYFRL-UHFFFAOYSA-N 1-[(4-chlorophenyl)-phenylmethyl]-4-methyl-1,4-diazepane Chemical compound C1CN(C)CCCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 WEUCDJCFJHYFRL-UHFFFAOYSA-N 0.000 description 1
- FAJGKPMGLMWSKW-UHFFFAOYSA-N 1-phenyl-1,4-diazepane Chemical compound C1CCNCCN1C1=CC=CC=C1 FAJGKPMGLMWSKW-UHFFFAOYSA-N 0.000 description 1
- SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical compound OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000028004 allergic respiratory disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229950008315 homochlorcyclizine Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
æ¬çºæã¯ãå»è¬åãšããŠåªããäœçšãæããæ°
èŠãªããªãã€ãªã³èªå°äœããã³ãã®è£œé æ¹æ³ã«é¢
ãããæŽã«è©³ããã¯ãäžè¬åŒ ãåŒäžïŒžã¯åŒâïŒCH2ïŒoâïŒåŒäžïœã¯ïŒãïŒã®
æŽæ°ãæå³ããïŒã§ç€ºãããåºïŒãŸã㯠åŒ
èŠãªããªãã€ãªã³èªå°äœããã³ãã®è£œé æ¹æ³ã«é¢
ãããæŽã«è©³ããã¯ãäžè¬åŒ ãåŒäžïŒžã¯åŒâïŒCH2ïŒoâïŒåŒäžïœã¯ïŒãïŒã®
æŽæ°ãæå³ããïŒã§ç€ºãããåºïŒãŸã㯠åŒ
ãåŒãã§ç€ºãããåºãæå³ã
ããã¯äœçŽã¢ã«ãã«åºïŒ
åŒ
ãåŒãïŒåŒäžïŒ¡ã¯åŒâïŒCH2ïŒnâ
ïŒåŒäžïœã¯ïŒãïŒã®æŽæ°ãæå³ããïŒã§ç€ºããã
åºïŒåŒ
åºïŒåŒ
ãåŒãã§ç€ºãããåºïŒåŒ
ãåŒãã§
瀺ãããåºïŒãŸãã¯åŒâCOâCHïŒCHâã§ç€ºã
ããåºãæå³ããY1ïŒY2ïŒããã³Y3ã¯åäžãŸã
ã¯çžç°ãªãæ°ŽçŽ ååïŒäœçŽã¢ã«ãã«åºïŒäœçŽã¢ã«
ã³ãã·åºïŒäœçŽã¢ã«ãã«ã¹ã«ããã«åºïŒããã²ã³
ååïŒãŸãã¯ãããåºãæå³ããïŒïŒåŒââ
OHïŒåŒäžïŒºã¯åŒâïŒCH2ïŒaâïŒåŒäžïœã¯ïŒãïŒ
ã®æŽæ°ãæå³ããïŒã§ç€ºãããåºïŒãŸãã¯åŒ
ããåºãæå³ããY1ïŒY2ïŒããã³Y3ã¯åäžãŸã
ã¯çžç°ãªãæ°ŽçŽ ååïŒäœçŽã¢ã«ãã«åºïŒäœçŽã¢ã«
ã³ãã·åºïŒäœçŽã¢ã«ãã«ã¹ã«ããã«åºïŒããã²ã³
ååïŒãŸãã¯ãããåºãæå³ããïŒïŒåŒââ
OHïŒåŒäžïŒºã¯åŒâïŒCH2ïŒaâïŒåŒäžïœã¯ïŒãïŒ
ã®æŽæ°ãæå³ããïŒã§ç€ºãããåºïŒãŸãã¯åŒ
ãåŒãã§ç€ºãããåºãæå³ããïŒã§ç€º
ãããåºïŒåŒâCOR1ïŒåŒäžR1ã¯æ°ŽçŽ ååïŒãŸã
ã¯äœçŽã¢ã«ãã«åºãæå³ããïŒïŒãŸãã¯åŒ
ã¯äœçŽã¢ã«ãã«åºãæå³ããïŒïŒãŸãã¯åŒ
ãåŒãã§ç€ºãããåºãæå³ããããã§è¡š
ããããããªãã€ãªã³èªå°äœããã³ãã®é
žä»å
å¡©ïŒãªãã³ã«ãã®è£œé æ¹æ³ã«é¢ãããã®ã§ããã äžèšäžè¬åŒããã«ãããŠãY1ïŒY2ïŒY3ïŒã
ãã³R1ã®å®çŸ©äžã«ã¿ãããäœçŽã¢ã«ãã«åºïŒäœ
çŽã¢ã«ã³ãã·åºïŒãŸãã¯äœçŽã¢ã«ãã«ã¹ã«ããã«
åºãšã¯ãççŽ æ°ïŒãïŒã®çŽéè¥ããã¯åæç¶ã®ã¢
ã«ãã«åºïŒäŸãã°ã¡ãã«ïŒãšãã«ïŒïœâããã
ã«ïŒã€ãœãããã«ïŒã€ãœããã«ïŒïŒâã¡ãã«ãã
ãã«ïŒtertâããã«ïŒïœâãã³ãã«ïŒïŒâãšãã«
ãããã«ïŒã€ãœã¢ãã«ïŒïœâããã·ã«åºãªã©ã®ã¢
ã«ãã«åºè¥ããã¯ããã«åºã¥ãã¢ã«ã³ãã·åºïŒã¹
ã«ããã«åºãæå³ããã ãŸãããã²ã³ååãšã¯å ·äœçã«ã¯å¡©çŽ ïŒèçŽ ïŒ
ãšãŠçŽ ïŒããçŽ ãæå³ããã ãŸãæ¬çºæã®ååç©ããã¯ãè¬ççã«èš±å®¹ã
ããç¡æ©é žãŸãã¯ææ©é žãšåå¿ãããŠå®¹æã«é žå
å å¡©ãšããããšãã§ããããããç¡æ©é žãšããŠã¯
å¡©é žïŒèåæ°ŽçŽ é žïŒãšãŠåæ°ŽçŽ é žïŒç¡«é žãªã©ãã
ãŸãææ©é žãšããŠã¯ãã¬ã€ã³é žïŒãããŒã«é žïŒã³
ãã¯é žïŒé ¢é žïŒããã³é žïŒã¯ãšã³é žïŒå®æ¯éŠé žãª
ã©ãäŸç€ºããããšãã§ããã æ¬çºæã®ä»£è¡šçãªååç©ãšããŠã¯äŸãã°ä»¥äžã®
ååç©ããããããã ïŒâïœãïŒâããšãã«ãã¢ããã©ãžãâ(1)ãã¡ã
ã«ïœâããªãã€ãªã³ ïŒâïœãïŒâã¡ãã«ãã¢ããã©ãžãâ(1)ãã¡ã
ã«ïœâããªãã€ãªã³ ïŒïœãïŒââã¯ãããã³ãžã«ãã¢ããã©ãžãâ
(1)ãã¡ãã«ïœâããªãã€ãªã³ ïŒâïœãïŒâãã«ãã«ãã¢ããã©ãžãâ(1)ããšã
ã«ïœâããªãã€ãªã³ ïŒâïœãïŒâã¡ãã«ãã¢ããã©ãžãâ(1)ããšã
ã«ïœâããªãã€ãªã³ ïŒâïœãïŒâããšãã«ãã¢ããã©ãžãâ(1)ããšã
ã«ïœâããªãã€ãªã³ ïŒâïœãïŒââã¯ãããã³ãžã«ãã¢ããã©ãžã
â(1)ããšãã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒïŒïŒïŒâãžã¯ãããã³ãžã«ïŒãã¢
ããã©ãžãâ(1)ããšãã«ïœâããªãã€ãªã³ ïŒâïœãïŒâã¡ãã«ãã¢ããã©ãžãâ(1)ãããã
ã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒïŒâããããã·ãšãã«ïŒãã¢ãã
ã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒïŒâããããã·ãããã«ïŒãã¢ã
ãã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒïŒâããããã·ãããã«ïŒãã¢ã
ãã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâãããã«ã«ã«ããã«ïŒãã¢ããã©ãž
ãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒïŒâããªãžã«ïŒãã¢ããã©ãžãâ
(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâããšãã«ãã¢ããã©ãžãâ(1)ããã
ãã«ïœâããªãã€ãªã³ ïŒâïœãïŒâãã³ãžã«ãã¢ããã©ãžãâ(1)ããã
ãã«ïœâããªãã€ãªã³ ïŒâïœãïŒââã¯ãããã³ãžã«ãã¢ããã©ãžã
â(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒïŒâã¯ãããã³ãžã«ïŒãã¢ããã©
ãžãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒïŒïŒïŒâãžã¯ãããã³ãžã«ïŒãã¢
ããã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒïŒïŒïŒâãžã¯ãããã³ãžã«ïŒãã¢
ããã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒââãã«ãªããã³ãžã«ãã¢ããã©ãž
ãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒââããããã³ãžã«ãã¢ããã©ãžã
â(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒââã¡ããã·ãã³ãžã«ãã¢ããã©ãž
ãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒïŒïŒïŒâãžã¡ããã·ãã³ãžã«ïŒã
ã¢ããã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒïŒïŒïŒïŒïŒâããªã¡ããã·ãã³ãž
ã«ïŒãã¢ããã©ãžãâ(1)ããããã«ïœâããªãã€
ãªã³ ïŒâïœãïŒâïŒïŒïŒïŒâãžã¡ããã·ãã³ãžã«ïŒã
ã¢ããã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒããªããžãã«ïŒãã¢ããã©ãžãâ
(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒïŒïŒïŒâãžã¯ãããã³ãŸã€ã«ïŒã
ã¢ããã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒââã¡ãã«ã¹ã«ããã«ãã³ãŸã€ã«ã
ã¢ããã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒã¡ãã«ããšãã«ã¡ãã«ïŒãã¢ãã
ã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâããšããã«ãã¢ããã©ãžãâ(1)ãã
ããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒããšãã«ããã«ã«ã«ããã«ïŒãã¢
ããã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒââã¯ãããã³ãžã«ãã¢ããã©ãžã
â(1)ãããã«ïœâããªãã€ãªã³ ïŒâïœãïŒââãã«ãªããã³ãžã«ãã¢ããã©ãž
ãâ(1)ãããã«ïœâããªãã€ãªã³ ïŒâïœãïŒââããããã³ãžã«ãã¢ããã©ãžã
â(1)ãããã«ïœâããªãã€ãªã³ æ¬çºæã«ãã€ãŠæäŸãããããªãã€ãªã³èªå°äœ
ã¯ãããããæç®æªåèŒã®æ°èŠååç©ã§ããã極
ããŠäœæ¯æ§ã§æç¶çãã€èããæãã¹ã¿ãã³äœçš
ãæããååç©ã§ãããåçš®ã®ã¢ã¬ã«ã®ãŒæ§åŒåž
çŸæ£ïŒã¢ã¬ã«ã®ãŒæ§éŒ»çïŒæ°ç®¡æ¯åæ¯ãªã©ïŒïŒã
ãã³ã¢ã¬ã«ã®ãŒæ§ç®èçŸæ£ïŒè麻ç¹ïŒæ¹¿ç¹ïŒç®è
çïŒççãªã©ïŒã®æ²»çã«æçšã§ãããæŽã«æ¬çº
æã«ãã€ãŠæäŸãããããªãã€ãªã³èªå°äœã¯ãè
ããè¡ç®¡æ¡åŒµäœçšãæããååç©ã§ãããããªã
ã¡ãæ¬çºæååç©ã¯ãæ«æ¢¢è¡æµã®æ¹åã®ã¿ãªã
ããè³åã³å ç¶åèã«ãããè¡æµã®æ¹åãé¡èã§
ããããããã€ãŠãæ«æ¢¢è¡æµæœ æµã®é害ã«åºã¥ã
çš®ã ã®çŸæ£ã®æ²»çå€ïŒè³è¡ç®¡é害åã³ãã®åŸéºç
ã®æ¹åïŒçå¿çïŒå¿ç硬å¡ãªã©ã®æ²»çå€ãšããŠæ
çšã§ããã æ¬çºæã®ååç©ããã¯ãçš®ã ã®æ¹æ³ã«ãã€ãŠ
補é ããããšãã§ãããããã®äžã§éåžžçšããã
ãæ¹æ³ã®äžäŸã瀺ãã°æ¬¡ã®åŠãã§ããã (1) 補é æ³ïŒ¡ïŒ åŒäžHalã¯ããã²ã³ååãæå³ããåã³ïŒ²ã¯
åèšã®æå³ãæãããïŒ ããªãã¡ãäžè¬åŒïŒïŒã§è¡šããããååç©
ãšãäžè¬åŒïŒïŒã§è¡šããããååç©ãšãåå¿ã
ããŠç®çååç©ïŒïŒãåŸãã æ¬åå¿ã¯ãç¡æº¶åªãŸãã¯ãäŸãã°ã¡ã¿ããŒã«ïŒ
ãšã¿ããŒã«ïŒãããããŒã«ïŒã€ãœãããããŒã«ç
ã®äœçŽã¢ã«ã³ãŒã«ç³»ïŒãã³ãŒã³ïŒãã«ãšã³ïŒãã·
ã¬ã³çã®ãã³ãŒã³ç³»ïŒãšãã«ãšãŒãã«ïŒããã©ã
ã€ãããã©ã³çã®ãšãŒãã«ç³»æº¶åªããåå¿ã«é¢äž
ããªã溶åªãé©å®éžæããŠäœ¿çšããããšãã§ã
ããåå¿ã¯å®€æž©ã§ãé²è¡ãããã奜ãŸããã¯æº¶åª
ã®æ²žç¹ãŸã§å ç±ããããšãæãŸãããåå¿ã«éã
ãŠã¯ãäŸãã°ããªãšãã«ã¢ãã³ïŒéçé žã¢ã«ã«
ãªïŒçé žã¢ã«ã«ãªïŒããªãžã³çã®è±é žå€ãåå¿ç³»
ã«æ·»å ããããšã«ãããåå¿ãäžå±€åæ»ã«ãããª
ãããšãã§ããã (2) 補é æ³ïŒ¢ïŒ ç®çååç©ïŒïŒã«ãããŠããåŒâïŒCH2ïŒo
âã§ç€ºãããåºã§ããå ŽåïŒïœïŒïŒã®å Žåã¯æ¬¡ã«
瀺ãæ¹æ³ã«ãã€ãŠã補é ã§ããã ïŒåŒäžïŒ²ã¯åèšã®æå³ãæããïŒ ããªãã¡ãäžè¬åŒïŒïŒã§è¡šããããååç©ãš
äžè¬åŒïŒïŒã§è¡šããããååç©åã³ãã«ããªã³
ãšãã¡ã¿ããŒã«ïŒãããããŒã«ïŒã€ãœãããããŒ
ã«çã®äœçŽã¢ã«ã³ãŒã«ç³»æº¶åªã䜿çšããŠåå¿ãã
ããåå¿ã¯éæµäžã§ãããªãã (3) 補é æ³ïŒ£ïŒ ïŒåŒäžHalã¯ããã²ã³ååãæå³ããããã³
ã¯åèšã®æå³ãæãããïŒ ããªãã¡ãäžè¬åŒïŒïŒã§è¡šããããååç©
ãšãäžè¬åŒïŒïŒã§è¡šããããååç©ãšãåå¿ã
ããŠç®çååç©ïŒïŒãåŸãã äŸãã°ïŒ²ãåŒ
å¡©ïŒãªãã³ã«ãã®è£œé æ¹æ³ã«é¢ãããã®ã§ããã äžèšäžè¬åŒããã«ãããŠãY1ïŒY2ïŒY3ïŒã
ãã³R1ã®å®çŸ©äžã«ã¿ãããäœçŽã¢ã«ãã«åºïŒäœ
çŽã¢ã«ã³ãã·åºïŒãŸãã¯äœçŽã¢ã«ãã«ã¹ã«ããã«
åºãšã¯ãççŽ æ°ïŒãïŒã®çŽéè¥ããã¯åæç¶ã®ã¢
ã«ãã«åºïŒäŸãã°ã¡ãã«ïŒãšãã«ïŒïœâããã
ã«ïŒã€ãœãããã«ïŒã€ãœããã«ïŒïŒâã¡ãã«ãã
ãã«ïŒtertâããã«ïŒïœâãã³ãã«ïŒïŒâãšãã«
ãããã«ïŒã€ãœã¢ãã«ïŒïœâããã·ã«åºãªã©ã®ã¢
ã«ãã«åºè¥ããã¯ããã«åºã¥ãã¢ã«ã³ãã·åºïŒã¹
ã«ããã«åºãæå³ããã ãŸãããã²ã³ååãšã¯å ·äœçã«ã¯å¡©çŽ ïŒèçŽ ïŒ
ãšãŠçŽ ïŒããçŽ ãæå³ããã ãŸãæ¬çºæã®ååç©ããã¯ãè¬ççã«èš±å®¹ã
ããç¡æ©é žãŸãã¯ææ©é žãšåå¿ãããŠå®¹æã«é žå
å å¡©ãšããããšãã§ããããããç¡æ©é žãšããŠã¯
å¡©é žïŒèåæ°ŽçŽ é žïŒãšãŠåæ°ŽçŽ é žïŒç¡«é žãªã©ãã
ãŸãææ©é žãšããŠã¯ãã¬ã€ã³é žïŒãããŒã«é žïŒã³
ãã¯é žïŒé ¢é žïŒããã³é žïŒã¯ãšã³é žïŒå®æ¯éŠé žãª
ã©ãäŸç€ºããããšãã§ããã æ¬çºæã®ä»£è¡šçãªååç©ãšããŠã¯äŸãã°ä»¥äžã®
ååç©ããããããã ïŒâïœãïŒâããšãã«ãã¢ããã©ãžãâ(1)ãã¡ã
ã«ïœâããªãã€ãªã³ ïŒâïœãïŒâã¡ãã«ãã¢ããã©ãžãâ(1)ãã¡ã
ã«ïœâããªãã€ãªã³ ïŒïœãïŒââã¯ãããã³ãžã«ãã¢ããã©ãžãâ
(1)ãã¡ãã«ïœâããªãã€ãªã³ ïŒâïœãïŒâãã«ãã«ãã¢ããã©ãžãâ(1)ããšã
ã«ïœâããªãã€ãªã³ ïŒâïœãïŒâã¡ãã«ãã¢ããã©ãžãâ(1)ããšã
ã«ïœâããªãã€ãªã³ ïŒâïœãïŒâããšãã«ãã¢ããã©ãžãâ(1)ããšã
ã«ïœâããªãã€ãªã³ ïŒâïœãïŒââã¯ãããã³ãžã«ãã¢ããã©ãžã
â(1)ããšãã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒïŒïŒïŒâãžã¯ãããã³ãžã«ïŒãã¢
ããã©ãžãâ(1)ããšãã«ïœâããªãã€ãªã³ ïŒâïœãïŒâã¡ãã«ãã¢ããã©ãžãâ(1)ãããã
ã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒïŒâããããã·ãšãã«ïŒãã¢ãã
ã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒïŒâããããã·ãããã«ïŒãã¢ã
ãã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒïŒâããããã·ãããã«ïŒãã¢ã
ãã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâãããã«ã«ã«ããã«ïŒãã¢ããã©ãž
ãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒïŒâããªãžã«ïŒãã¢ããã©ãžãâ
(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâããšãã«ãã¢ããã©ãžãâ(1)ããã
ãã«ïœâããªãã€ãªã³ ïŒâïœãïŒâãã³ãžã«ãã¢ããã©ãžãâ(1)ããã
ãã«ïœâããªãã€ãªã³ ïŒâïœãïŒââã¯ãããã³ãžã«ãã¢ããã©ãžã
â(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒïŒâã¯ãããã³ãžã«ïŒãã¢ããã©
ãžãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒïŒïŒïŒâãžã¯ãããã³ãžã«ïŒãã¢
ããã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒïŒïŒïŒâãžã¯ãããã³ãžã«ïŒãã¢
ããã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒââãã«ãªããã³ãžã«ãã¢ããã©ãž
ãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒââããããã³ãžã«ãã¢ããã©ãžã
â(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒââã¡ããã·ãã³ãžã«ãã¢ããã©ãž
ãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒïŒïŒïŒâãžã¡ããã·ãã³ãžã«ïŒã
ã¢ããã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒïŒïŒïŒïŒïŒâããªã¡ããã·ãã³ãž
ã«ïŒãã¢ããã©ãžãâ(1)ããããã«ïœâããªãã€
ãªã³ ïŒâïœãïŒâïŒïŒïŒïŒâãžã¡ããã·ãã³ãžã«ïŒã
ã¢ããã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒããªããžãã«ïŒãã¢ããã©ãžãâ
(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒïŒïŒïŒâãžã¯ãããã³ãŸã€ã«ïŒã
ã¢ããã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒââã¡ãã«ã¹ã«ããã«ãã³ãŸã€ã«ã
ã¢ããã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒã¡ãã«ããšãã«ã¡ãã«ïŒãã¢ãã
ã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâããšããã«ãã¢ããã©ãžãâ(1)ãã
ããã«ïœâããªãã€ãªã³ ïŒâïœãïŒâïŒããšãã«ããã«ã«ã«ããã«ïŒãã¢
ããã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ ïŒâïœãïŒââã¯ãããã³ãžã«ãã¢ããã©ãžã
â(1)ãããã«ïœâããªãã€ãªã³ ïŒâïœãïŒââãã«ãªããã³ãžã«ãã¢ããã©ãž
ãâ(1)ãããã«ïœâããªãã€ãªã³ ïŒâïœãïŒââããããã³ãžã«ãã¢ããã©ãžã
â(1)ãããã«ïœâããªãã€ãªã³ æ¬çºæã«ãã€ãŠæäŸãããããªãã€ãªã³èªå°äœ
ã¯ãããããæç®æªåèŒã®æ°èŠååç©ã§ããã極
ããŠäœæ¯æ§ã§æç¶çãã€èããæãã¹ã¿ãã³äœçš
ãæããååç©ã§ãããåçš®ã®ã¢ã¬ã«ã®ãŒæ§åŒåž
çŸæ£ïŒã¢ã¬ã«ã®ãŒæ§éŒ»çïŒæ°ç®¡æ¯åæ¯ãªã©ïŒïŒã
ãã³ã¢ã¬ã«ã®ãŒæ§ç®èçŸæ£ïŒè麻ç¹ïŒæ¹¿ç¹ïŒç®è
çïŒççãªã©ïŒã®æ²»çã«æçšã§ãããæŽã«æ¬çº
æã«ãã€ãŠæäŸãããããªãã€ãªã³èªå°äœã¯ãè
ããè¡ç®¡æ¡åŒµäœçšãæããååç©ã§ãããããªã
ã¡ãæ¬çºæååç©ã¯ãæ«æ¢¢è¡æµã®æ¹åã®ã¿ãªã
ããè³åã³å ç¶åèã«ãããè¡æµã®æ¹åãé¡èã§
ããããããã€ãŠãæ«æ¢¢è¡æµæœ æµã®é害ã«åºã¥ã
çš®ã ã®çŸæ£ã®æ²»çå€ïŒè³è¡ç®¡é害åã³ãã®åŸéºç
ã®æ¹åïŒçå¿çïŒå¿ç硬å¡ãªã©ã®æ²»çå€ãšããŠæ
çšã§ããã æ¬çºæã®ååç©ããã¯ãçš®ã ã®æ¹æ³ã«ãã€ãŠ
補é ããããšãã§ãããããã®äžã§éåžžçšããã
ãæ¹æ³ã®äžäŸã瀺ãã°æ¬¡ã®åŠãã§ããã (1) 補é æ³ïŒ¡ïŒ åŒäžHalã¯ããã²ã³ååãæå³ããåã³ïŒ²ã¯
åèšã®æå³ãæãããïŒ ããªãã¡ãäžè¬åŒïŒïŒã§è¡šããããååç©
ãšãäžè¬åŒïŒïŒã§è¡šããããååç©ãšãåå¿ã
ããŠç®çååç©ïŒïŒãåŸãã æ¬åå¿ã¯ãç¡æº¶åªãŸãã¯ãäŸãã°ã¡ã¿ããŒã«ïŒ
ãšã¿ããŒã«ïŒãããããŒã«ïŒã€ãœãããããŒã«ç
ã®äœçŽã¢ã«ã³ãŒã«ç³»ïŒãã³ãŒã³ïŒãã«ãšã³ïŒãã·
ã¬ã³çã®ãã³ãŒã³ç³»ïŒãšãã«ãšãŒãã«ïŒããã©ã
ã€ãããã©ã³çã®ãšãŒãã«ç³»æº¶åªããåå¿ã«é¢äž
ããªã溶åªãé©å®éžæããŠäœ¿çšããããšãã§ã
ããåå¿ã¯å®€æž©ã§ãé²è¡ãããã奜ãŸããã¯æº¶åª
ã®æ²žç¹ãŸã§å ç±ããããšãæãŸãããåå¿ã«éã
ãŠã¯ãäŸãã°ããªãšãã«ã¢ãã³ïŒéçé žã¢ã«ã«
ãªïŒçé žã¢ã«ã«ãªïŒããªãžã³çã®è±é žå€ãåå¿ç³»
ã«æ·»å ããããšã«ãããåå¿ãäžå±€åæ»ã«ãããª
ãããšãã§ããã (2) 補é æ³ïŒ¢ïŒ ç®çååç©ïŒïŒã«ãããŠããåŒâïŒCH2ïŒo
âã§ç€ºãããåºã§ããå ŽåïŒïœïŒïŒã®å Žåã¯æ¬¡ã«
瀺ãæ¹æ³ã«ãã€ãŠã補é ã§ããã ïŒåŒäžïŒ²ã¯åèšã®æå³ãæããïŒ ããªãã¡ãäžè¬åŒïŒïŒã§è¡šããããååç©ãš
äžè¬åŒïŒïŒã§è¡šããããååç©åã³ãã«ããªã³
ãšãã¡ã¿ããŒã«ïŒãããããŒã«ïŒã€ãœãããããŒ
ã«çã®äœçŽã¢ã«ã³ãŒã«ç³»æº¶åªã䜿çšããŠåå¿ãã
ããåå¿ã¯éæµäžã§ãããªãã (3) 補é æ³ïŒ£ïŒ ïŒåŒäžHalã¯ããã²ã³ååãæå³ããããã³
ã¯åèšã®æå³ãæãããïŒ ããªãã¡ãäžè¬åŒïŒïŒã§è¡šããããååç©
ãšãäžè¬åŒïŒïŒã§è¡šããããååç©ãšãåå¿ã
ããŠç®çååç©ïŒïŒãåŸãã äŸãã°ïŒ²ãåŒ
ãåŒãïŒåŒäžY1ïŒ
Y2ïŒããã³Y3ã¯åèšã®æå³ãæãããïŒã§ç€ºãã
ãåºã®å Žåã®å ·äœäŸã瀺ãã°æ¬¡ã®åŠããšãªãã ãŸããåŒâïŒCH2ïŒaâOHïŒåŒäžïœã¯åèšã®
æå³ãæããïŒã§ç€ºãããåºã®å Žåã®å ·äœäŸã瀺
ãã°æ¬¡ã®åŠããšãªãã æ¬åå¿ã¯ãç¡æº¶åªãŸãã¯äŸãã°ã¡ã¿ããŒã«ïŒãš
ã¿ããŒã«ïŒãããããŒã«ïŒã€ãœãããããŒã«çã®
äœçŽã¢ã«ã³ãŒã«ç³»ïŒãã³ãŒã³ïŒãã«ãšã³ïŒãã·ã¬
ã³çã®ãã³ãŒã³ç³»ïŒãšãã«ãšãŒãã«ïŒããã©ãã
ããã©ã³çã®ãšãŒãã«ç³»æº¶åªããåå¿ã«é¢äžããª
ã溶åªãé©å®éžæããŠäœ¿çšããããšãã§ãããå
å¿ã¯å®€æž©ã§ãé²è¡ããã奜ãŸããã¯æº¶åªã®æ²žç¹ãŸ
ã§å ç±ããããšãæãŸãããåå¿ã«éããŠã¯ãäŸ
ãã°ããªãšãã«ã¢ãã³ïŒéçé žã¢ã«ã«ãªïŒçé žã¢
ã«ã«ãªïŒããªãžã³çã®è±é žå€ãåå¿ç³»ã«æ·»å ãã
ããšã«ãããåå¿ãäžå±€åæ»ã«ãããªãããšãã§
ããã 次ã«æ¬çºæååç©ã®åªããè¬çäœçšãæ¬çºæã®
代衚çååç©ã«ã€ããŠä»¥äžã«èª¬æããã ïŒ æãã¹ã¿ãã³äœçš 絶é£ããéã¢ã«ã¢ããã®åè žãæåºãã26âã®
Tyrode液ãæºããããã°ãã¹ç®¡äžã«æžåãã1.5
ïœã®è² è·ãããã匵åãçå°ºæ§ã«èšé²ããã
10-6Mã®ãã¹ã¿ãã³ãæ·»å ãïŒïŒååŸã«æ€äœïŒæ¬
çºæååç©åã³å¯Ÿç §è¬ïŒ10-6Mã10-8Mã®æ¿åºŠã«
ãªãããã«æ·»å ããåçž®åããã³æŽæµåŸã®å埩é
çšã芳å¯ãããå¯Ÿç §è¬ãšããŠã¯ããã¡ãµãžã³ïŒã·
ã³ããªãžã³ïŒãã¢ã¯ãããµã€ã¯ãªãžã³ãçšããã
çµæãè¡šïŒã«ç€ºãã
ãåºã®å Žåã®å ·äœäŸã瀺ãã°æ¬¡ã®åŠããšãªãã ãŸããåŒâïŒCH2ïŒaâOHïŒåŒäžïœã¯åèšã®
æå³ãæããïŒã§ç€ºãããåºã®å Žåã®å ·äœäŸã瀺
ãã°æ¬¡ã®åŠããšãªãã æ¬åå¿ã¯ãç¡æº¶åªãŸãã¯äŸãã°ã¡ã¿ããŒã«ïŒãš
ã¿ããŒã«ïŒãããããŒã«ïŒã€ãœãããããŒã«çã®
äœçŽã¢ã«ã³ãŒã«ç³»ïŒãã³ãŒã³ïŒãã«ãšã³ïŒãã·ã¬
ã³çã®ãã³ãŒã³ç³»ïŒãšãã«ãšãŒãã«ïŒããã©ãã
ããã©ã³çã®ãšãŒãã«ç³»æº¶åªããåå¿ã«é¢äžããª
ã溶åªãé©å®éžæããŠäœ¿çšããããšãã§ãããå
å¿ã¯å®€æž©ã§ãé²è¡ããã奜ãŸããã¯æº¶åªã®æ²žç¹ãŸ
ã§å ç±ããããšãæãŸãããåå¿ã«éããŠã¯ãäŸ
ãã°ããªãšãã«ã¢ãã³ïŒéçé žã¢ã«ã«ãªïŒçé žã¢
ã«ã«ãªïŒããªãžã³çã®è±é žå€ãåå¿ç³»ã«æ·»å ãã
ããšã«ãããåå¿ãäžå±€åæ»ã«ãããªãããšãã§
ããã 次ã«æ¬çºæååç©ã®åªããè¬çäœçšãæ¬çºæã®
代衚çååç©ã«ã€ããŠä»¥äžã«èª¬æããã ïŒ æãã¹ã¿ãã³äœçš 絶é£ããéã¢ã«ã¢ããã®åè žãæåºãã26âã®
Tyrode液ãæºããããã°ãã¹ç®¡äžã«æžåãã1.5
ïœã®è² è·ãããã匵åãçå°ºæ§ã«èšé²ããã
10-6Mã®ãã¹ã¿ãã³ãæ·»å ãïŒïŒååŸã«æ€äœïŒæ¬
çºæååç©åã³å¯Ÿç §è¬ïŒ10-6Mã10-8Mã®æ¿åºŠã«
ãªãããã«æ·»å ããåçž®åããã³æŽæµåŸã®å埩é
çšã芳å¯ãããå¯Ÿç §è¬ãšããŠã¯ããã¡ãµãžã³ïŒã·
ã³ããªãžã³ïŒãã¢ã¯ãããµã€ã¯ãªãžã³ãçšããã
çµæãè¡šïŒã«ç€ºãã
ãè¡šã
ãè¡šã
ãè¡šã
è¡šïŒãããæ¬çºæååç©ã¯ãæšæºè¬ã§ãããã
ã¡ãµãžã³ïŒã·ã³ããªãžã³ïŒãã¢ã¯ãã«ãµã€ã¯ãªãž
ã³ãšæ¯èŒããŠãå¹ååã³äœçšæç¶æ§ã®ãããã®ç¹
ã§ããåçè¥ããã¯ãã以äžã®æãã¹ã¿ãã³äœçš
ãæããããšãæããã§ããããããã€ãŠãæ¬çº
æååç©ã¯ãæãã¹ã¿ãã³å€ãšããŠæ¥µããŠæçšã§
ããã 以äžã«ãæ¬çºæãæŽã«è©³çŽ°ã«èª¬æããããå®æœ
äŸã瀺ãããæ¬çºæãããã®ã¿ã«éå®ãããããš
ããªãããšã¯ãããŸã§ããªãã å®æœäŸ ïŒ ïŒâïœãïŒâããšãã«ãã¢ããã©ãžãâ(1)ãã¡
ãã«ïœâããªãã€ãªã³ ããªãã€ãªã³1.8ïœïŒããšãã«ãã¢ããã©ãžã³
1.8ïœããã³37ïŒ ãã«ã ã¢ã«ããã1.2ïœããšã¿ã
ãŒã«æº¶åªäžïŒåééæµäžæ¹æãããåå¿åŸæåºã
ãçµæ¶ãåããã æšé¡ã®ïŒâïœãïŒâããšãã«ãã¢ããã©ãžãâ
(1)ãã¡ãã«ïœâããªãã€ãªã³2.2ïœãåŸãã è ç¹ïŒ106ã107â å çŽ åæå€ïŒC19H24O2N6ãšã㊠   çè«å€ïŒïŒ ïŒ 61.93 6.58 22.81 å®æž¬å€ïŒïŒ ïŒ 61.42 6.51 22.60 å®æœäŸ ïŒ ïŒâïœãïŒââã¯ãããã³ãžã«ãã¢ããã©ãž
ãâ(1)ããšãã«ïœâããªãã€ãªã³ ïŒâïŒïŒâããã¢ãšãã«ïŒããªãã€ãªã³4.3
ïœïŒïŒ°âã¯ãããã³ãžã«ãã¢ããã©ãžã³3.4ïœã
ãã³ããªãšãã«ã¢ãã³3.0ïœããã³ãŒã³æº¶åªäžïŒ
æééæµäžæ¹æãããããªãšãã«ã¢ãã³ã®å¡©é žå¡©
ãå»ãã液ãçšå¡©é žã§æœåºãããçšå¡©é žå±€ã
çšæ°Žé žåãããªãŠã ã§ã¢ã«ã«ãªæ§ã«ããåŸããã³
ãŒã³ã§æœåºããã溶åªãçå»ããŠåŸãããç²çµæ¶
ãã€ãœãããã«ã¢ã«ã³ãŒã«ã§åçµæ¶ããŠãæšé¡ã®
ïŒâïœãïŒââã¯ãããã³ãžã«ãã¢ããã©ãžã
â(1)ããšãã«ïœâããªãã€ãªã³3.2ïœãåŸãã è ç¹ïŒ114ã115â å çŽ åæå€ïŒC21H27O2N6Clãšã㊠   çè«å€ïŒïŒ ïŒ 58.52 6.33 19.78 å®æž¬å€ïŒïŒ ïŒ 58.56 6.33 19.78 å®æœäŸ ïŒ ïŒâïœãïŒâβâãã€ãããã·ãšãã«ãã¢ãã
ã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ã»å¡©é ž
å¡© (1) ïŒâãïŒâãã¢ããã©ãžãâ(1)ããããã«â
ããªãã€ãªã³ã®åæ ïŒâïŒïŒâããã¢ãããã«ïŒããªãã€ãªã³35
ïœïŒïŒ®âãã«ãã«ãã¢ããã©ãžã³15ïœïŒããã³ç¡
æ°Žçé žã«ãª16ïœããšã¿ããŒã«æº¶åªäž10æééæµäž
æ¹æããã次ãã§çé žã«ãªãå»ã液ãæžå§æ¿
çž®ãããæ®æž£ãçšå¡©é žã§å æ°Žå解ããããšã«ãã
ç®çç©è³ªã®ïŒâãïŒâãã¢ããã©ãžãã«â(1)ãã
ããã«âããªãã€ãªã³33ïœãåŸãã (2) ïŒâïœãïŒâβâãã€ãããã·ãšãã«ãã¢ã
ãã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ã»å¡©
é žå¡©ã®åæ (1)ã«ãã€ãŠåŸãããïŒâãïŒâãã¢ããã©ãžã
â(1)ããããã«âããªãã€ãªã³3.2ïœïŒãšãã¬ã³
ã¯ãããããªã³1.6ïœïŒããã³ç¡æ°Žçé žã«ãª1.4ïœ
ããšã¿ããŒã«æº¶åªäž19æééæµäžæ¹æããã次ã
ã§çé žã«ãªãå»ã液ãæ¿çž®ãããæ®æž£ã«çšå¡©
é žãå ããã¯ãããã«ã ã§æŽæµããåŸãçšæ°Žé žå
ãããªãŠã ã§ã¢ã«ã«ãªæ§ã«ããåŸãæåºæ²¹ç¶ç©ã
ã¯ãããã«ã ã§æœåºããã溶åªãçå»åŸãåžžæ³ã«
ããå¡©é žå¡©ãšãããã¡ã¿ããŒã«ã§åçµæ¶ããŠæšé¡
ã®ïŒâïœãïŒâβâãã€ãããã·ãšãã«ãã¢ãã
ã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ã»å¡©é žå¡©
1.8ïœãåŸãã è ç¹ïŒ183ã186âïŒåè§£ïŒ å çŽ åæå€ïŒC17H28O3N6ã»2HClã»ïŒïŒïŒH2O    çè«å€ïŒïŒ ïŒ 45.73 7.01 18.83 å®æž¬å€ïŒïŒ ïŒ 45.20 7.18 18.59 å®æœäŸ ïŒ ïŒâïœãïŒâïŒïŒïŒïŒâãžã¯ãããã³ãžã«ïŒã
ã¢ããã©ãžãâ(1)ããããã«ïœâããªãã€ãª
ã³ã»å¡©é žå¡© ïŒâïŒïŒâããã¢ãããã«ïŒããªãã€ãªã³3.0
ïœïŒïŒ®âïŒïŒïŒïŒâãžã¯ãããã³ãžã«ïŒâãã¢ã
ãã©ãžã³2.6ïœïŒããã³ç¡æ°Žçé žã«ãª1.4ïœããšã¿
ããŒã«æº¶åªäž13æééæµäžæ¹æããã次ãã§çé ž
ã«ãªãå»ã液ãæ¿çž®ãããæ®æž£ã«çšå¡©é žãå
ããã¯ãããã«ã ã§æŽæµããåŸãçšæ°Žé žåãããª
ãŠã ã§ã¢ã«ã«ãªæ§ã«ããåŸãæåºæ²¹ç¶ç©ãã¯ãã
ãã«ã ã§æœåºããã溶åªãçå»åŸãåžžæ³ã«ããå¡©
é žå¡©ãšãããã¡ã¿ããŒã«ã»ãšã¿ããŒã«æ··æ¶²ã§åçµ
æ¶ããŠæšé¡ã®ïŒâïœãïŒâïŒïŒïŒïŒâãžã¯ããã
ã³ãžã«ïŒãã¢ããã©ãžãâ(1)ããããã«ïœâããª
ãã€ãªã³ã»å¡©é žå¡©3.1ïœãåŸãã è ç¹ïŒ250ã255â å çŽ åæå€ïŒC22H28O2N6Cl2ã»2HClã»ïŒïŒïŒH2O ãšã㊠   çè«å€ïŒïŒ ïŒ 47.06 5.58 14.97 å®æž¬å€ïŒïŒ ïŒ 47.36 5.75 14.49 å®æœäŸ ïŒ ïŒâïœãïŒâïŒïŒïŒïŒâãžã¯ãããã³ãŸã€ã«ïŒ
ãã¢ããã©ãžãâ(1)ãâãããã«ïœâããªãã€
ãªã³ã»å¡©é žå¡© ïŒâãïŒâãã¢ããã©ãžãâ(1)ããããã«âã
ãªãã€ãªã³4.8ïœïŒ10ïŒ çé žã«ãªæ°Žæº¶æ¶²42ïœïŒã¯
ãããã«ã 100mlã®æ··å溶液ãæ°·å·æ¹æäžãïŒïŒ
ïŒâãžã¯ãããã³ãŸã€ã«ã¯ãã©ã€ã3.2ïœã®ã¯ã
ããã«ã 溶液ã滎äžãããã¯ãããã«ã å±€ãåå
ããæ°ŽæŽïŒä¹Ÿç¥ããã溶åªçå»åŸïŒåžžæ³ã«ããå¡©
é žå¡©ãšãããã¡ã¿ããŒã«ïŒé ¢é žãšãã«ã§åçµæ¶ã
ãŠæšé¡ã®ïŒâïœãïŒâïŒïŒïŒïŒâãžã¯ãããã³ãŸ
ã€ã«ïŒãã¢ããã©ãžãâ(1)ãâãããã«ïœâããª
ãã€ãªã³ã»å¡©é žå¡©3.0ïœãåŸãã è ç¹ïŒ163ã167â å çŽ åæå€ïŒC22H26O3N6Cl2ã»HClã»2H2O ãšã㊠   çè«å€ïŒïŒ ïŒ 46.69 5.53 14.85 å®æž¬å€ïŒïŒ ïŒ 46.88 5.15 15.49 å®æœäŸïŒãå®æœäŸ35 å®æœäŸïŒãå®æœäŸ35ã¯ãå®æœäŸïŒãïŒã®æ¹æ³
ïŒåè¿°ãã補é æ¹æ³ïŒ¡ïŒã«æºããæ¹æ³ã«ãã次ã®
è¡šïŒã«ç€ºãããååç©ãåŸãããã
ã¡ãµãžã³ïŒã·ã³ããªãžã³ïŒãã¢ã¯ãã«ãµã€ã¯ãªãž
ã³ãšæ¯èŒããŠãå¹ååã³äœçšæç¶æ§ã®ãããã®ç¹
ã§ããåçè¥ããã¯ãã以äžã®æãã¹ã¿ãã³äœçš
ãæããããšãæããã§ããããããã€ãŠãæ¬çº
æååç©ã¯ãæãã¹ã¿ãã³å€ãšããŠæ¥µããŠæçšã§
ããã 以äžã«ãæ¬çºæãæŽã«è©³çŽ°ã«èª¬æããããå®æœ
äŸã瀺ãããæ¬çºæãããã®ã¿ã«éå®ãããããš
ããªãããšã¯ãããŸã§ããªãã å®æœäŸ ïŒ ïŒâïœãïŒâããšãã«ãã¢ããã©ãžãâ(1)ãã¡
ãã«ïœâããªãã€ãªã³ ããªãã€ãªã³1.8ïœïŒããšãã«ãã¢ããã©ãžã³
1.8ïœããã³37ïŒ ãã«ã ã¢ã«ããã1.2ïœããšã¿ã
ãŒã«æº¶åªäžïŒåééæµäžæ¹æãããåå¿åŸæåºã
ãçµæ¶ãåããã æšé¡ã®ïŒâïœãïŒâããšãã«ãã¢ããã©ãžãâ
(1)ãã¡ãã«ïœâããªãã€ãªã³2.2ïœãåŸãã è ç¹ïŒ106ã107â å çŽ åæå€ïŒC19H24O2N6ãšã㊠   çè«å€ïŒïŒ ïŒ 61.93 6.58 22.81 å®æž¬å€ïŒïŒ ïŒ 61.42 6.51 22.60 å®æœäŸ ïŒ ïŒâïœãïŒââã¯ãããã³ãžã«ãã¢ããã©ãž
ãâ(1)ããšãã«ïœâããªãã€ãªã³ ïŒâïŒïŒâããã¢ãšãã«ïŒããªãã€ãªã³4.3
ïœïŒïŒ°âã¯ãããã³ãžã«ãã¢ããã©ãžã³3.4ïœã
ãã³ããªãšãã«ã¢ãã³3.0ïœããã³ãŒã³æº¶åªäžïŒ
æééæµäžæ¹æãããããªãšãã«ã¢ãã³ã®å¡©é žå¡©
ãå»ãã液ãçšå¡©é žã§æœåºãããçšå¡©é žå±€ã
çšæ°Žé žåãããªãŠã ã§ã¢ã«ã«ãªæ§ã«ããåŸããã³
ãŒã³ã§æœåºããã溶åªãçå»ããŠåŸãããç²çµæ¶
ãã€ãœãããã«ã¢ã«ã³ãŒã«ã§åçµæ¶ããŠãæšé¡ã®
ïŒâïœãïŒââã¯ãããã³ãžã«ãã¢ããã©ãžã
â(1)ããšãã«ïœâããªãã€ãªã³3.2ïœãåŸãã è ç¹ïŒ114ã115â å çŽ åæå€ïŒC21H27O2N6Clãšã㊠   çè«å€ïŒïŒ ïŒ 58.52 6.33 19.78 å®æž¬å€ïŒïŒ ïŒ 58.56 6.33 19.78 å®æœäŸ ïŒ ïŒâïœãïŒâβâãã€ãããã·ãšãã«ãã¢ãã
ã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ã»å¡©é ž
å¡© (1) ïŒâãïŒâãã¢ããã©ãžãâ(1)ããããã«â
ããªãã€ãªã³ã®åæ ïŒâïŒïŒâããã¢ãããã«ïŒããªãã€ãªã³35
ïœïŒïŒ®âãã«ãã«ãã¢ããã©ãžã³15ïœïŒããã³ç¡
æ°Žçé žã«ãª16ïœããšã¿ããŒã«æº¶åªäž10æééæµäž
æ¹æããã次ãã§çé žã«ãªãå»ã液ãæžå§æ¿
çž®ãããæ®æž£ãçšå¡©é žã§å æ°Žå解ããããšã«ãã
ç®çç©è³ªã®ïŒâãïŒâãã¢ããã©ãžãã«â(1)ãã
ããã«âããªãã€ãªã³33ïœãåŸãã (2) ïŒâïœãïŒâβâãã€ãããã·ãšãã«ãã¢ã
ãã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ã»å¡©
é žå¡©ã®åæ (1)ã«ãã€ãŠåŸãããïŒâãïŒâãã¢ããã©ãžã
â(1)ããããã«âããªãã€ãªã³3.2ïœïŒãšãã¬ã³
ã¯ãããããªã³1.6ïœïŒããã³ç¡æ°Žçé žã«ãª1.4ïœ
ããšã¿ããŒã«æº¶åªäž19æééæµäžæ¹æããã次ã
ã§çé žã«ãªãå»ã液ãæ¿çž®ãããæ®æž£ã«çšå¡©
é žãå ããã¯ãããã«ã ã§æŽæµããåŸãçšæ°Žé žå
ãããªãŠã ã§ã¢ã«ã«ãªæ§ã«ããåŸãæåºæ²¹ç¶ç©ã
ã¯ãããã«ã ã§æœåºããã溶åªãçå»åŸãåžžæ³ã«
ããå¡©é žå¡©ãšãããã¡ã¿ããŒã«ã§åçµæ¶ããŠæšé¡
ã®ïŒâïœãïŒâβâãã€ãããã·ãšãã«ãã¢ãã
ã©ãžãâ(1)ããããã«ïœâããªãã€ãªã³ã»å¡©é žå¡©
1.8ïœãåŸãã è ç¹ïŒ183ã186âïŒåè§£ïŒ å çŽ åæå€ïŒC17H28O3N6ã»2HClã»ïŒïŒïŒH2O    çè«å€ïŒïŒ ïŒ 45.73 7.01 18.83 å®æž¬å€ïŒïŒ ïŒ 45.20 7.18 18.59 å®æœäŸ ïŒ ïŒâïœãïŒâïŒïŒïŒïŒâãžã¯ãããã³ãžã«ïŒã
ã¢ããã©ãžãâ(1)ããããã«ïœâããªãã€ãª
ã³ã»å¡©é žå¡© ïŒâïŒïŒâããã¢ãããã«ïŒããªãã€ãªã³3.0
ïœïŒïŒ®âïŒïŒïŒïŒâãžã¯ãããã³ãžã«ïŒâãã¢ã
ãã©ãžã³2.6ïœïŒããã³ç¡æ°Žçé žã«ãª1.4ïœããšã¿
ããŒã«æº¶åªäž13æééæµäžæ¹æããã次ãã§çé ž
ã«ãªãå»ã液ãæ¿çž®ãããæ®æž£ã«çšå¡©é žãå
ããã¯ãããã«ã ã§æŽæµããåŸãçšæ°Žé žåãããª
ãŠã ã§ã¢ã«ã«ãªæ§ã«ããåŸãæåºæ²¹ç¶ç©ãã¯ãã
ãã«ã ã§æœåºããã溶åªãçå»åŸãåžžæ³ã«ããå¡©
é žå¡©ãšãããã¡ã¿ããŒã«ã»ãšã¿ããŒã«æ··æ¶²ã§åçµ
æ¶ããŠæšé¡ã®ïŒâïœãïŒâïŒïŒïŒïŒâãžã¯ããã
ã³ãžã«ïŒãã¢ããã©ãžãâ(1)ããããã«ïœâããª
ãã€ãªã³ã»å¡©é žå¡©3.1ïœãåŸãã è ç¹ïŒ250ã255â å çŽ åæå€ïŒC22H28O2N6Cl2ã»2HClã»ïŒïŒïŒH2O ãšã㊠   çè«å€ïŒïŒ ïŒ 47.06 5.58 14.97 å®æž¬å€ïŒïŒ ïŒ 47.36 5.75 14.49 å®æœäŸ ïŒ ïŒâïœãïŒâïŒïŒïŒïŒâãžã¯ãããã³ãŸã€ã«ïŒ
ãã¢ããã©ãžãâ(1)ãâãããã«ïœâããªãã€
ãªã³ã»å¡©é žå¡© ïŒâãïŒâãã¢ããã©ãžãâ(1)ããããã«âã
ãªãã€ãªã³4.8ïœïŒ10ïŒ çé žã«ãªæ°Žæº¶æ¶²42ïœïŒã¯
ãããã«ã 100mlã®æ··å溶液ãæ°·å·æ¹æäžãïŒïŒ
ïŒâãžã¯ãããã³ãŸã€ã«ã¯ãã©ã€ã3.2ïœã®ã¯ã
ããã«ã 溶液ã滎äžãããã¯ãããã«ã å±€ãåå
ããæ°ŽæŽïŒä¹Ÿç¥ããã溶åªçå»åŸïŒåžžæ³ã«ããå¡©
é žå¡©ãšãããã¡ã¿ããŒã«ïŒé ¢é žãšãã«ã§åçµæ¶ã
ãŠæšé¡ã®ïŒâïœãïŒâïŒïŒïŒïŒâãžã¯ãããã³ãŸ
ã€ã«ïŒãã¢ããã©ãžãâ(1)ãâãããã«ïœâããª
ãã€ãªã³ã»å¡©é žå¡©3.0ïœãåŸãã è ç¹ïŒ163ã167â å çŽ åæå€ïŒC22H26O3N6Cl2ã»HClã»2H2O ãšã㊠   çè«å€ïŒïŒ ïŒ 46.69 5.53 14.85 å®æž¬å€ïŒïŒ ïŒ 46.88 5.15 15.49 å®æœäŸïŒãå®æœäŸ35 å®æœäŸïŒãå®æœäŸ35ã¯ãå®æœäŸïŒãïŒã®æ¹æ³
ïŒåè¿°ãã補é æ¹æ³ïŒ¡ïŒã«æºããæ¹æ³ã«ãã次ã®
è¡šïŒã«ç€ºãããååç©ãåŸãããã
ãè¡šã
ãè¡šã
ãè¡šã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ äžè¬åŒ ãåŒäžïŒžã¯åŒâïŒCH3ïŒoâïŒåŒäžïœã¯ïŒãïŒã®
æŽæ°ãæå³ããïŒã§ç€ºãããåºïŒãŸãã¯åŒ
ãåŒãã§ç€ºãããåºãæå³ããã ã¯äœçŽã¢ã«ãã«åºïŒ åŒãåŒãïŒåŒäžïŒ¡ã¯åŒâïŒCH2ïŒnâ ïŒåŒäžïœã¯ïŒãïŒã®æŽæ°ãæå³ããïŒã§ç€ºãã
ãåºãåŒãåŒãã§ç€ºãããåºïŒ åŒãåŒãã§ç€ºãããåºïŒãŸã㯠åŒâCOâCHïŒCHâã§ç€ºãããåºãæå³ãã
Y1ïŒY2ããã³Y3ã¯åäžãŸãã¯çžéãªãæ°ŽçŽ å
åïŒäœçŽã¢ã«ãã«åºïŒäœçŽã¢ã«ã³ãã·åºãäœçŽã¢
ã«ãã«ã¹ã«ããã«åºïŒããã²ã³ååïŒãŸãã¯ãã
ãåºãæå³ãããïŒã§ç€ºãããåºïŒ åŒââOHïŒåŒäžïŒºã¯åŒâïŒCH2ïŒaâïŒåŒäžïœ
ã¯ïŒãïŒã®æŽæ°ãæå³ãããïŒã§ç€ºãããåºïŒãŸ
ãã¯åŒãåŒãã§ç€ºãããåºãæå³ã ããïŒã§ç€ºãããåºïŒåŒâCOR1ïŒåŒäžR1ã¯æ°ŽçŽ
ååïŒãŸãã¯äœçŽã¢ã«ãã«åºãæå³ãããïŒïŒãŸã
ã¯åŒãåŒãã§ç€ºãããåºãæå³ãããã ã§è¡šããããããªãã€ãªã³èªå°äœããã³ãã®é žä»
å å¡©ã ïŒ äžè¬åŒ ãåŒäžïœã¯ïŒãïŒã®æŽæ°ãæå³ããã ã¯ïŒäœçŽã¢ã«ãã«åºïŒåŒãåŒã ïŒåŒäžïŒ¡ã¯åŒâïŒCH2ïŒnâïŒåŒäžïœã¯ïŒãïŒã®æŽ
æ°ãæå³ããïŒã§ç€ºãããåºïŒ åŒãåŒãã§ç€ºãããåºïŒåŒãåŒãã§ç€ºã ããåºïŒãŸãã¯åŒâCOâCHïŒCHâã§ç€ºããã
åºãæå³ããY1ïŒY2ããã³Y3ã¯åäžãŸãã¯çžç°
ãªãæ°ŽçŽ ååïŒäœçŽã¢ã«ãã«åºïŒäœçŽã¢ã«ã³ãã·
åºïŒäœçŽã¢ã«ãã«ã¹ã«ããã«åºïŒããã²ã³ååïŒ
ãŸãã¯ãããåºãæå³ãããïŒã åŒââOHïŒåŒäžïŒºã¯åŒâïŒCH2ïŒaâïŒåŒäžïœ
ã¯ïŒãïŒã®æŽæ°ãæå³ããïŒã§ç€ºãããåºïŒãŸã
ã¯åŒãåŒãã§ç€ºãããåºãæå³ããã ïŒã§ç€ºãããåºïŒåŒâCOR1ïŒåŒäžR1ã¯æ°ŽçŽ å
åïŒãŸãã¯äœçŽã¢ã«ãã«åºãæå³ãããïŒïŒãŸãã¯
åŒãåŒãã§ç€ºãããåºãæå³ãããïŒã§ è¡šããããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ããªãã€
ãªã³èªå°äœããã³ãã®é žä»å é žã ïŒ äžè¬åŒ ãåŒäžïœã¯ïŒãïŒã®æŽæ°ãæå³ãã㯠åŒâïŒCH2ïŒnâïŒåŒäžïœã¯ïŒãïŒã®æŽæ°ãæå³ã
ãïŒã§ç€ºãããåºãæå³ããY1ïŒY2ïŒããã³Y3
ã¯åäžãŸãã¯çžç°ãªãæ°ŽçŽ ååïŒäœçŽã¢ã«ãã«
åºïŒäœçŽã¢ã«ã³ãã·åºïŒäœçŽã¢ã«ãã«ã¹ã«ããã«
åºïŒããã²ã³ååïŒãŸãã¯ãããåºãæå³ã
ãããã§è¡šããããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®
ããªãã€ãªã³èªå°äœããã³ãã®é žåå å¡©ã ïŒ äžè¬åŒ ãåŒäžHa1ã¯ããã²ã³ååãæå³ããã¯åŒâ
ïŒCH2ïŒoâïŒåŒäžïœã¯ïŒãïŒã®æŽæ°ãæå³ããïŒ
ã§ç€ºãããåºïŒãŸãã¯åŒãåŒã㧠瀺ãããåºãæå³ããããã§è¡šããããååç©
ã«ã äžè¬åŒ ãåŒäžïŒ²ã¯äœçŽã¢ã«ãã«åºïŒåŒ
ãåŒã ïŒåŒäžïŒ¡ã¯åŒâïŒCH2ïŒnâïŒåŒäžïœã¯ïŒãïŒã®æŽ
æ°ãæå³ããïŒã§ç€ºãããåºïŒåŒãåŒãã§ç€º ãããåºïŒ åŒãåŒãã§ç€ºãããåºïŒ ãŸãã¯åŒâCOâCHïŒCHâã§ç€ºãããåºãæ
å³ããY1ïŒY2ïŒããã³Y3ã¯åäžãŸãã¯çžç°ãªã
æ°ŽçŽ ååïŒäœçŽã¢ã«ãã«åºïŒäœçŽã¢ã«ã³ãã·åºïŒ
äœçŽã¢ã«ãã«ã¹ã«ããã«åºïŒããã²ã³ååïŒãŸã
ã¯ãããåºãæå³ãããïŒã§ç€ºãããåºïŒåŒâ
âOHïŒåŒäžïŒºã¯åŒâïŒCH2ïŒaâïŒåŒäžïœã¯ïŒã
ïŒã®æŽæ°ãæå³ãããïŒã§ç€ºãããåºïŒãŸãã¯åŒ
ãåŒãã§ç€ºãããåºãæå³ãããïŒã§ 瀺ãããåºïŒåŒâCOR1ïŒåŒäžR1ã¯æ°ŽçŽ ååïŒãŸ
ãã¯äœçŽã¢ã«ãã«åºãæå³ãããïŒïŒãŸãã¯åŒ
ãåŒãã§ç€ºãããåºãæå³ããããã§è¡š ããããååç©ãåå¿ãããããšãç¹åŸŽãšããäž
è¬åŒ ïŒåŒäžïŒžããã³ïŒ²ã¯åèšããæå³ãæããïŒã§
è¡šããããããªãã€ãªã³èªå°äœã®è£œé æ¹æ³ã ïŒ äžè¬åŒ ãåŒäžïŒžã¯åŒâïŒCH2ïŒoâïŒåŒäžïœã¯ïŒãïŒã®
æŽæ°ãæå³ããïŒã§ç€ºãããåºïŒãŸã㯠åŒãåŒãã§ç€ºãããåºãæå³ã ãããã§è¡šããããååç©ã«ïŒäžè¬åŒHalâ
ãåŒäžïŒ²ã¯äœçŽã¢ã«ãã«åºïŒ åŒãåŒãïŒåŒäžïŒ¡ã¯âïŒCH2ïŒnâåŒäž ïœã¯ïŒãïŒã®æŽæ°ãæå³ããïŒã§ç€ºãããåºïŒåŒ
ãåŒãã§ç€ºãããåºïŒåŒãåŒãã§ç€ºãã ãåºïŒãŸãã¯åŒâCOâCHïŒCHâã§ç€ºãããåº
ãæå³ãïŒY1ïŒY2ïŒããã³Y3ã¯åäžãŸãã¯çžç°
ãªãæ°ŽçŽ ååïŒäœçŽã¢ã«ãã«åºïŒäœçŽã¢ã«ã³ãã·
åºïŒäœçŽã¢ã«ãã«ã¹ã«ããã«åºïŒããã²ã³ååïŒ
ãŸãã¯ãããåºãæå³ããïŒã§ç€ºãããåºïŒ åŒââOHïŒåŒäžïŒºã¯åŒâïŒCH2ïŒaâïŒåŒäžïœ
ã¯ïŒãïŒã®æŽæ°ãæå³ããïŒã§ç€ºãããåºïŒãŸã
ã¯åŒãåŒãã§ç€ºãããåºãæå³ããã ïŒã§ç€ºãããåºïŒåŒâCOR1ïŒåŒäžR1ã¯æ°ŽçŽ å
åïŒãŸãã¯äœçŽã¢ã«ãã«åºãæå³ããïŒïŒãŸãã¯
åŒãåŒãã§ç€ºãããåºãæå³ãããã㧠衚ããããååç©ãåå¿ãããããšãç¹åŸŽãšãã
äžè¬åŒ ïŒåŒäžïŒžããã³ïŒ²ã¯åèšããæå³ãæããïŒã§
è¡šããããããªãã€ãªã³èªå°äœã®è£œé æ¹æ³ã ïŒ åŒ ã§è¡šããããããªãã€ãªã³ãšããã«ã ã¢ã«ããã
ããã³äžè¬åŒ ãåŒäžïŒ²ã¯äœçŽã¢ã«ãã«åºïŒåŒ
ãåŒã ïŒåŒäžïŒ¡ã¯âïŒCH2ïŒnâïŒåŒäžïœã¯ïŒãïŒã®æŽæ°
ãæå³ããïŒã§ç€ºãããåºïŒåŒãåŒãã§ç€ºã ããåºïŒåŒãåŒãã§ç€ºãããåºïŒãŸã㯠åŒâCOâCHïŒCHâã§ç€ºãããåºãæå³ãïŒ
Y1ïŒY2ïŒããã³Y3ã¯åäžãŸãã¯çžç°ãªãæ°ŽçŽ å
åïŒäœçŽã¢ã«ãã«åºïŒäœçŽã¢ã«ã³ãã·åºïŒäœçŽã¢
ã«ãã«ã¹ã«ããã«åºïŒããã²ã³ååïŒãŸãã¯ãã
ãåºãæå³ããïŒã§ç€ºãããåºïŒ åŒââOHïŒåŒäžïŒºã¯åŒâïŒCH2ïŒaâïŒåŒäžïœ
ã¯ïŒãïŒã®æŽæ°ãæå³ããïŒã§ç€ºãããåºïŒãŸã
ã¯åŒãåŒãã§ç€ºãããåºãæå³ããã ïŒã§ç€ºãããåºïŒåŒâCOR1ïŒåŒäžR1ã¯æ°ŽçŽ å
åïŒãŸãã¯äœçŽã¢ã«ãã«åºãæå³ããïŒïŒãŸã㯠åŒãåŒãã§ç€ºãããåºãæå³ãããã㧠衚ããããååç©ãåå¿ãããããšãç¹åŸŽãšãã
äžè¬åŒ ïŒåŒäžïŒ²ã¯åèšã®æå³ãæããïŒã§è¡šãããã
ããªãã€ãªã³èªå°äœã®è£œé æ¹æ³ã
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9363579A JPS5618983A (en) | 1979-07-25 | 1979-07-25 | Theophylline derivative and its preapration |
| EP80104372A EP0023350A1 (en) | 1979-07-25 | 1980-07-24 | Theophylline derivatives, a process for the preparation of the same and a therapeutical composition |
| CA357,051A CA1130283A (en) | 1979-07-25 | 1980-07-25 | Theophylline derivatives and process for the preparation of the same |
| US06/528,678 US4599414A (en) | 1979-07-25 | 1983-09-01 | Theophylline derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9363579A JPS5618983A (en) | 1979-07-25 | 1979-07-25 | Theophylline derivative and its preapration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5618983A JPS5618983A (en) | 1981-02-23 |
| JPS6140234B2 true JPS6140234B2 (ja) | 1986-09-08 |
Family
ID=14087792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9363579A Granted JPS5618983A (en) | 1979-07-25 | 1979-07-25 | Theophylline derivative and its preapration |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US4599414A (ja) |
| EP (1) | EP0023350A1 (ja) |
| JP (1) | JPS5618983A (ja) |
| CA (1) | CA1130283A (ja) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH648559A5 (de) * | 1981-07-20 | 1985-03-29 | Siegfried Ag | Theophyllinderivate und verfahren zu deren herstellung. |
| US4400381A (en) * | 1981-07-31 | 1983-08-23 | Laroche-Navarron, S.A. | Piperazine derivatives of theophylline |
| EP0087810B1 (en) * | 1982-03-02 | 1986-06-25 | Eisai Co., Ltd. | Antiphlogistic/antipyretic/analgesic pharmaceutical compositions containing theophylline derivatives as active ingredient |
| FR2531085A1 (fr) * | 1982-07-28 | 1984-02-03 | Adir | Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant |
| US4673684A (en) * | 1984-04-04 | 1987-06-16 | Terumo Corporation | Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient |
| US5473070A (en) * | 1992-11-16 | 1995-12-05 | Cell Therapeutics, Inc. | Substituted long chain alcohol xanthine compounds |
| US6693105B1 (en) | 1992-11-16 | 2004-02-17 | Cell Therapeutics, Inc. | Hydroxyl-containing compounds |
| US5804584A (en) * | 1992-11-16 | 1998-09-08 | Cell Therapeutics, Inc. | Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms |
| DK1027336T3 (da) * | 1997-10-27 | 2005-01-24 | Neurosearch As | Heteroaryldiazacycloalkaner, deres fremstilling og anvendelse |
| US20030207901A1 (en) * | 1999-07-27 | 2003-11-06 | Cell Therapeutics, Inc. | Hydroxyl-containing compounds |
| US7550468B2 (en) * | 2000-07-28 | 2009-06-23 | Ing-Jun Chen | Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase |
| US11413769B1 (en) | 2018-09-24 | 2022-08-16 | Quantum Innovations, Inc. | End effector assembly and method for robot-enabled manipulation of round objects |
| US11505859B1 (en) | 2018-09-24 | 2022-11-22 | Quantum Innovations, Inc. | Ophthalmic substrate conveyor and method of conveying ophthalmic substrates for vacuum deposition |
| CN110174363A (zh) * | 2019-01-09 | 2019-08-27 | å京ä¹åŒºçç©ææ¯è¡ä»œæéå ¬åž | 6-ç£·é žè¡èç³è±æ°¢é ¶çªåäœåå ¶åšå¶å€æ£æµè¯åäžççšé |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1620576A1 (de) * | 1966-11-25 | 1970-02-26 | Troponwerke Dinklage & Co | Verfahren zur Herstellung von Theophyllin- und Theobrominverbindungen |
| JPS5564761A (en) * | 1978-11-09 | 1980-05-15 | Ohayoo Nyugyo Kk | Preparation of granular ice and its device |
| JPS55118488A (en) * | 1979-03-05 | 1980-09-11 | Eisai Co Ltd | Theobromine derivative and its preparation |
-
1979
- 1979-07-25 JP JP9363579A patent/JPS5618983A/ja active Granted
-
1980
- 1980-07-24 EP EP80104372A patent/EP0023350A1/en not_active Withdrawn
- 1980-07-25 CA CA357,051A patent/CA1130283A/en not_active Expired
-
1983
- 1983-09-01 US US06/528,678 patent/US4599414A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US4599414A (en) | 1986-07-08 |
| JPS5618983A (en) | 1981-02-23 |
| EP0023350A1 (en) | 1981-02-04 |
| CA1130283A (en) | 1982-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS609713B2 (ja) | ã«ã«ãã¹ããªã«èªå°äœ | |
| JPS6140234B2 (ja) | ||
| KR870001268B1 (ko) | í¬ì°íŽ ì ë첎ì ì ì¡° ë°©ë² | |
| EP0515265B1 (fr) | Dérivés de la pyrimidine, leur procédé de préparation, les intermédiaires obtenus, leur application à titre de médicaments et les compositions pharmaceutiques les renfermant | |
| EP0217700B1 (fr) | Derives de benzimidazole, leur preparation et leur application en therapeutique | |
| JPH0681750B2 (ja) | ãã³ãŸãã©ã³èªå°äœ | |
| JP2006511439A (ja) | å»è¬äžæå¹ãªååç©ïŒã°ã©ãã»ããã³ïŒã®è£œé æ¹æ³ | |
| JP2012512237A (ja) | ã¢ãã°ã¬ãªãã®è£œé æ³ | |
| TW202014415A (zh) | 賜床æ¿å°Œ(cerdulatinib)ä¹åæ | |
| EP1339719B1 (fr) | Derives de benzimidazole, leur preparation et leur application en therapeutique | |
| JPS6355512B2 (ja) | ||
| JPS6141915B2 (ja) | ||
| FR2693197A1 (fr) | Nouveaux dérivés de quinoléine, leur procédé de préparation et leur application thérapeutique. | |
| US3751462A (en) | Process for preparation of substituted fluoromethanesulfonanilides | |
| JPH01121274A (ja) | ïŒâ眮æã·ã¯ããããã€ãããŸãŒã«èªå°äœãæ朰çå€äžŠã³ã«ãã®è£œæ³ | |
| JPS6257620B2 (ja) | ||
| JP4571505B2 (ja) | ïŒâïŒâïŒãã³ãºã€ãããŸãŒã«âïŒâã€ã«ããªïŒãšãã«ïŒœããã©ãžã³åã¯ãã®å¡©ã®è£œé æ³ | |
| WO2024084491A1 (en) | Process for synthesis of res metirom and its intermediates thereof | |
| JPH09255669A (ja) | æ°èŠãªãã³ãžãªãã³èªå°äœ | |
| JPS59186963A (ja) | æ°èŠãªããšãã«ããã©ãžã³èªå°äœ | |
| JPS633859B2 (ja) | ||
| JPS6379874A (ja) | ã€ãœã€ã³ãâã«èªå°äœ | |
| JPS6160831B2 (ja) | ||
| JPH0639466B2 (ja) | ãŠã¬ã¢èªå°äœ | |
| JPS61155371A (ja) | ïŒâã¢ã·ã«ã¢ããâïŒïŒïŒïŒïŒïŒïŒâããã©ãããâïŒïŒïŒâã¡ã¿ãã€ãœãããªã³èªå°äœããã³æ朰çå€ |